Evidence map›Paper›PMID 36518037›Full record

ArticleCurrent pharmaceutical design2023

Insulin Signaling Pathway Model in Adipocyte Cells.

Monir Sheibani, Farhang Jalali-Farahani, Reza Zarghami, Sima Sadrai

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Monir SheibaniPharmaceutical Engineering Laboratory, Pharmaceutical Process Centers of Excellence, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Farhang Jalali-FarahaniPharmaceutical Engineering Laboratory, Pharmaceutical Process Centers of Excellence, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Reza ZarghamiPharmaceutical Engineering Laboratory, Pharmaceutical Process Centers of Excellence, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Sima SadraiDepartment of Pharmaceutics, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
University of Tehran · IRTehran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWorldwide, type 2 diabetes mellitus (T2DM) is one of the most pervasive and fastgrowing disorders, bringing long-term adverse effects. T2DM arises from pancreatic β-cells deficiency to produce enough insulin or when the body cannot effectively use the insulin produced by such cells. Accordingly, early diagnosis will decrease the long-term effects and high-healthcare costs of diabetes.

objectiveThe objective is developing an integrated mathematical model of the insulin signaling network based on Brännmark's model, which can simulate the signaling events more comprehensively with the added key components.

methodsIn this study, a thorough mathematical model of the insulin signaling network was developed by expanding the previously validated model and incorporating the glycogen synthesis module. Parameters (69 parameters) of the integrated model were evaluated by a genetic algorithm by fitting the model predictions to eighty percent of experimental data from the literature. Twenty percent of the experimental data were used to evaluate the final optimized model.

resultsThe time-response curves indicate that the GS phosphorylation reaches its maximum in response to 10

conclusionConsiderably, the trends of all signaling components simulated by the expanded model shows high compatibility with experimental data (R2 ≥ 0.9), which approves the accuracy of the proposed model. The proposed mathematical model can be used in many biological systems and combined with the whole-body model of the blood glucose regulation system for a better understanding of the causes and potential treatment of type 2 diabetes. Although, this model is not a complete description of insulin signaling, yet it can make profound contributions to improvements regarding other important components and signaling branches such as epidermal growth factor (EGF) signaling, as well as signaling in other cell types in the model structure of future works.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceAdipocytesGlycogen Synthase Kinase 3HumansInsulinPhosphorylationSignal TransductionGlycogen Synthase Kinase 3Insulinadipocyte cellsdiabetesepidermal growth factorglycogenInsulin signalingmathematical modeling

Identifiers

PMID36518037
OpenAlexW4311576091

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.